Medical management of thyrotropin-secreting pituitary adenomas

Paolo Beck-Peccoz, Luca Persani

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Thyrotropin-secreting pituitary tumors (TSH-omas) are a rare cause of hyperthyroidism and account for less than 1% of all pituitary adenomas. It is however noteworthy that the number of reported cases tripled in the last years as a consequence of the routine use of ultrasensitive immunometric assays for measuring TSH levels. Contrary to previous RIAs, ultrasensitive TSH assays allow a clear distinction between patients with suppressed and those with non-suppressed circulating TSH concentrations, i.e. between patients with primary hyperthyroidism (Graves' disease or toxic nodular goiter) and those with central hyperthyroidism (TSH-oma or pituitary resistance to thyroid hormone action). Failure to recognize the presence of a TSH-oma may result in dramatic consequences, such as improper thyroid ablation that may cause the pituitary tumor volume to further expand. The medical treatment of TSH-omas mainly rests on the administration of somatostatin analogs, such as octreotide and lanreotide. In fact, administration of dopamine agonists failed to persistently block TSH secretion in almost all patients and caused tumor shrinkage only in those with combined hypersecretion of TSH and PRL. On the contrary, somatostatin analogs were effective in reducing TSH and α-subunit secretion in more than 90% of cases with consequent normalization, of FT4 and FT3 levels and restoration of the euthyroid state in the majority of them. In about one third of patients, a clear shrinkage of tumor mass and vision improvement could be demonstrated. Tachyphylaxis, cholelithiasis and carbohydrate intolerance occurred in a minority of treated patients. Whether somatostatin analog treatment may be an alternative to surgery and/or irradiation in patients with TSH-oma remains to be established. Nonetheless, the long-acting somatostatin preparations represent a useful tool for long-term treatment of such a rare pituitary tumors.

Original languageEnglish
Pages (from-to)83-88
Number of pages6
JournalPituitary
Volume5
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Pituitary Neoplasms
Thyrotropin
Somatostatin
Hyperthyroidism
Thyroid Hormone Resistance Syndrome
Nodular Goiter
Tachyphylaxis
Cholelithiasis
Octreotide
Poisons
Graves Disease
Dopamine Agonists
Tumor Burden
Neoplasms
Thyroid Gland
Therapeutics

Keywords

  • Dopaminergic drugs (cabergoline, bromocriptine)
  • Glycoprotein hormone α-subunit (α-GSU)
  • Somatostatin analogs (octreotide, lanreotide)
  • Thyrotropin (thyroid stimulating hormone, TSH)
  • TSH-secreting pituitary adenomas (TSH-omas)

ASJC Scopus subject areas

  • Endocrinology

Cite this

Medical management of thyrotropin-secreting pituitary adenomas. / Beck-Peccoz, Paolo; Persani, Luca.

In: Pituitary, Vol. 5, No. 2, 2002, p. 83-88.

Research output: Contribution to journalArticle

Beck-Peccoz, Paolo ; Persani, Luca. / Medical management of thyrotropin-secreting pituitary adenomas. In: Pituitary. 2002 ; Vol. 5, No. 2. pp. 83-88.
@article{8ab910ed74ee439b9e595a6806e1498b,
title = "Medical management of thyrotropin-secreting pituitary adenomas",
abstract = "Thyrotropin-secreting pituitary tumors (TSH-omas) are a rare cause of hyperthyroidism and account for less than 1{\%} of all pituitary adenomas. It is however noteworthy that the number of reported cases tripled in the last years as a consequence of the routine use of ultrasensitive immunometric assays for measuring TSH levels. Contrary to previous RIAs, ultrasensitive TSH assays allow a clear distinction between patients with suppressed and those with non-suppressed circulating TSH concentrations, i.e. between patients with primary hyperthyroidism (Graves' disease or toxic nodular goiter) and those with central hyperthyroidism (TSH-oma or pituitary resistance to thyroid hormone action). Failure to recognize the presence of a TSH-oma may result in dramatic consequences, such as improper thyroid ablation that may cause the pituitary tumor volume to further expand. The medical treatment of TSH-omas mainly rests on the administration of somatostatin analogs, such as octreotide and lanreotide. In fact, administration of dopamine agonists failed to persistently block TSH secretion in almost all patients and caused tumor shrinkage only in those with combined hypersecretion of TSH and PRL. On the contrary, somatostatin analogs were effective in reducing TSH and α-subunit secretion in more than 90{\%} of cases with consequent normalization, of FT4 and FT3 levels and restoration of the euthyroid state in the majority of them. In about one third of patients, a clear shrinkage of tumor mass and vision improvement could be demonstrated. Tachyphylaxis, cholelithiasis and carbohydrate intolerance occurred in a minority of treated patients. Whether somatostatin analog treatment may be an alternative to surgery and/or irradiation in patients with TSH-oma remains to be established. Nonetheless, the long-acting somatostatin preparations represent a useful tool for long-term treatment of such a rare pituitary tumors.",
keywords = "Dopaminergic drugs (cabergoline, bromocriptine), Glycoprotein hormone α-subunit (α-GSU), Somatostatin analogs (octreotide, lanreotide), Thyrotropin (thyroid stimulating hormone, TSH), TSH-secreting pituitary adenomas (TSH-omas)",
author = "Paolo Beck-Peccoz and Luca Persani",
year = "2002",
doi = "10.1023/A:1022360414062",
language = "English",
volume = "5",
pages = "83--88",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Medical management of thyrotropin-secreting pituitary adenomas

AU - Beck-Peccoz, Paolo

AU - Persani, Luca

PY - 2002

Y1 - 2002

N2 - Thyrotropin-secreting pituitary tumors (TSH-omas) are a rare cause of hyperthyroidism and account for less than 1% of all pituitary adenomas. It is however noteworthy that the number of reported cases tripled in the last years as a consequence of the routine use of ultrasensitive immunometric assays for measuring TSH levels. Contrary to previous RIAs, ultrasensitive TSH assays allow a clear distinction between patients with suppressed and those with non-suppressed circulating TSH concentrations, i.e. between patients with primary hyperthyroidism (Graves' disease or toxic nodular goiter) and those with central hyperthyroidism (TSH-oma or pituitary resistance to thyroid hormone action). Failure to recognize the presence of a TSH-oma may result in dramatic consequences, such as improper thyroid ablation that may cause the pituitary tumor volume to further expand. The medical treatment of TSH-omas mainly rests on the administration of somatostatin analogs, such as octreotide and lanreotide. In fact, administration of dopamine agonists failed to persistently block TSH secretion in almost all patients and caused tumor shrinkage only in those with combined hypersecretion of TSH and PRL. On the contrary, somatostatin analogs were effective in reducing TSH and α-subunit secretion in more than 90% of cases with consequent normalization, of FT4 and FT3 levels and restoration of the euthyroid state in the majority of them. In about one third of patients, a clear shrinkage of tumor mass and vision improvement could be demonstrated. Tachyphylaxis, cholelithiasis and carbohydrate intolerance occurred in a minority of treated patients. Whether somatostatin analog treatment may be an alternative to surgery and/or irradiation in patients with TSH-oma remains to be established. Nonetheless, the long-acting somatostatin preparations represent a useful tool for long-term treatment of such a rare pituitary tumors.

AB - Thyrotropin-secreting pituitary tumors (TSH-omas) are a rare cause of hyperthyroidism and account for less than 1% of all pituitary adenomas. It is however noteworthy that the number of reported cases tripled in the last years as a consequence of the routine use of ultrasensitive immunometric assays for measuring TSH levels. Contrary to previous RIAs, ultrasensitive TSH assays allow a clear distinction between patients with suppressed and those with non-suppressed circulating TSH concentrations, i.e. between patients with primary hyperthyroidism (Graves' disease or toxic nodular goiter) and those with central hyperthyroidism (TSH-oma or pituitary resistance to thyroid hormone action). Failure to recognize the presence of a TSH-oma may result in dramatic consequences, such as improper thyroid ablation that may cause the pituitary tumor volume to further expand. The medical treatment of TSH-omas mainly rests on the administration of somatostatin analogs, such as octreotide and lanreotide. In fact, administration of dopamine agonists failed to persistently block TSH secretion in almost all patients and caused tumor shrinkage only in those with combined hypersecretion of TSH and PRL. On the contrary, somatostatin analogs were effective in reducing TSH and α-subunit secretion in more than 90% of cases with consequent normalization, of FT4 and FT3 levels and restoration of the euthyroid state in the majority of them. In about one third of patients, a clear shrinkage of tumor mass and vision improvement could be demonstrated. Tachyphylaxis, cholelithiasis and carbohydrate intolerance occurred in a minority of treated patients. Whether somatostatin analog treatment may be an alternative to surgery and/or irradiation in patients with TSH-oma remains to be established. Nonetheless, the long-acting somatostatin preparations represent a useful tool for long-term treatment of such a rare pituitary tumors.

KW - Dopaminergic drugs (cabergoline, bromocriptine)

KW - Glycoprotein hormone α-subunit (α-GSU)

KW - Somatostatin analogs (octreotide, lanreotide)

KW - Thyrotropin (thyroid stimulating hormone, TSH)

KW - TSH-secreting pituitary adenomas (TSH-omas)

UR - http://www.scopus.com/inward/record.url?scp=0036937865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036937865&partnerID=8YFLogxK

U2 - 10.1023/A:1022360414062

DO - 10.1023/A:1022360414062

M3 - Article

C2 - 12675505

AN - SCOPUS:0036937865

VL - 5

SP - 83

EP - 88

JO - Pituitary

JF - Pituitary

SN - 1386-341X

IS - 2

ER -